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A B S T R A C T
In observational studies, vitamin D deficiency is a risk factor for low bone density and future fractures, whereas a
causal relation has been difficult to show in randomized controlled trials (RCTs). Similarly, vitamin D deficiency
has been associated with increased bone turnover, but RCTs with vitamin D have not shown conclusive effects.
This could be due to inclusion of vitamin D sufficient subjects and low vitamin D doses. In the present study 399
subjects with mean baseline serum 25-hydroxyvitamin D (25(OH)D) 34.0 nmol/L completed a four months in-
tervention with vitamin D3 20,000 IU per week versus placebo. Mean serum 25(OH)D increased to 89.0 nmol/L
in the vitamin D group and decreased slightly in the placebo group. A small, but significant, decrease in the bone
formation marker procollagen of type 1 amino-terminal propeptide (P1NP) was seen in the vitamin D group as
compared to the placebo group (mean delta P1NP -1.2 pg/mL and 1.5 ng/mL, respectively, P < 0.01). No
significant effects were seen on serum carboxyl-terminal telopeptide of type 1 collagen (CTX-1), Dickkopf-1,
sclerostin, tumor necrosis factor-alpha, osteoprotegerin, receptor activator of nuclear factor ĸB ligand, or leptin.
Subgroup analyses on subjects with low baseline serum 25(OH)D did not yield additional, significant results. In
subjects with high baseline serum parathyroid hormone (PTH) > 6.5 pmol/L and post-intervention decrease in
PTH, the decrease in P1NP was more pronounced, they also exhibited significantly reduced serum CTX-1 and
increased serum sclerostin. In conclusion, supplementation with vitamin D appears to suppress bone turnover,
possibly mediated by PTH reduction. Our findings need to be confirmed in even larger cohorts with vitamin D
insufficient subjects.
1. Introduction
Vitamin D facilitates intestinal calcium absorption and thereby
provide calcium necessary for bone mineralization [1]. Prolonged and
severe vitamin D deficiency leads to rickets in children and osteoma-
lacia in adults, and it is important with vitamin D supplements to
prevent this in those at risk [2]. Consequently, recommendations re-
garding vitamin D intake and what can be considered a sufficient serum
level of 25-hydroxyvitamin D (25(OH)D), which is a marker of vitamin
D status, are based upon bone health [3]. The vitamin D receptor
(VDR), as well as enzymes necessary for hydroxylation of vitamin D to
its active form 1,25-dihydroxyvitamin D, are present in tissues
throughout the body, and therefore vitamin D may possibly also have
extra-skeletal effects [4]. In observational studies, vitamin D deficiency
is associated with a number of diseases and an increased mortality risk,
but positive effects of vitamin D have been hard to demonstrate in
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randomized controlled trials (RCTs) [5].
There is a positive cross-sectional association between bone mineral
density (BMD) and serum levels of 25(OH)D [6,7]. However, most in-
terventional studies have failed to show effects of vitamin D supple-
mentation on BMD and fracture prevention [8]. This may, as has been
the case for vitamin D RCTs in general, be attributed to adequate vi-
tamin D status in the study subjects [9]. Thus, in a study of in-
stitutionalized patients with apparently severe vitamin D deficiency,
significant benefits were demonstrated [10].
The skeleton undergoes a constant remodeling with a delicate bal-
ance between bone resorption and bone formation, which is orche-
strated by the osteocytes. The activity of this process can be monitored
by serum levels of bone turnover markers (BTMs). Carboxyl-terminal
telopeptide of type 1 collagen (CTX-1) and procollagen of type 1 amino-
terminal propeptide (P1NP), which are markers of bone resorption and
bone formation, respectively, are useful for evaluating both anti-
resorptive and anabolic osteoporosis treatment [11]. Whether these
markers are suitable in assessing the skeletal effects of vitamin D sup-
plementation is not settled, and so far, studies on the effect of vitamin D
supplementation on BTMs have been diverging [12–14].
In the present study, we included subjects with serum 25(OH)D
levels below 42 nmol/L at screening, gave a weekly vitamin D3 dose of
20,000 IU, and evaluated effects on CTX-1 and P1NP, and also on
several factors involved in bone metabolism.
2. Methods
2.1. Subjects and study design
The main endpoint of the study was change in cardiovascular risk
factors, and the design of the study and these results have previously
been reported in detail [15]. The study was performed in Tromsø,
northern Norway (69 degrees north), and the subjects were recruited
from the population-based Tromsø study [16], which was performed for
the seventh time in 2015–2016. In the Tromsø study all citizens
≥40 years (n= 32,591) were invited, 21,083 attended, and serum
25(OH)D was successfully measured in 20,922. Among these, 1489
subjects with serum values< 42 nmol/L and with age < 80 years were
invited to participate. Six hundred and thirty-nine responded and were
screened by phone regarding medical history, use of vitamin D sup-
plements, solarium on a regular basis, planned holiday(s) in tropical
areas during the study period, and for women<50 years, use of ac-
ceptable contraception. A total of 455 subjects passed this initial tele-
phone screening and met for the first visit at the Clinical Research Unit
at the University Hospital of North Norway where an informed consent
form was signed, clinical examinations performed, and fasting blood
samples drawn. These examinations did not reveal any contraindication
for participation in 422 subjects who then attended the next visit within
2–5 days. At this second visit, the study drugs (vitamin D3 (chole-
calciferol) capsules (20,000 IU (500 μg)) Dekristol, Mibe, Jena, Ger-
many) or identical looking placebo capsules containing arachis oil
(Ayanda GmbH & CoKG, Falkenhagen, Germany) were dispensed. Five
capsules were given as a loading dose followed by one capsule each
week. Measurement of BMD was performed at this visit in the last 336
subjects included.
The randomization was stratified according to gender, vitamin D
status in the Tromsø study (above/below 25 nmol/L), smoking status
and BMI above/below 27 kg/m2. All nurses, doctors, other study per-
sonnel and study participants were blinded throughout the study. The
subjects were asked not to take any vitamin D supplements (including
cod liver oil) or use solarium during the intervention period.
Four months later the third and fourth visits were performed,
identical to the first and the second. Compliance was calculated as the
ratio between capsules used (capsules supplied minus capsules re-
turned) and number of weeks between second and fourth visit.
2.2. Measurements
Serum calcium, parathyroid hormone (PTH) and 25(OH)D were
analyzed as previously described [17]. The serum 25(OH)D assay was
an in-house liquid chromatography–tandem mass spectrometry method
that detects both 25(OH)D3 and 25(OH)D2 and the sum of these are
presented as 25(OH)D in the results. CTX-1 and P1NP were measured
by electrochemiluminescence immunoassays with a Cobas e601 kit
(Roche Diagnostics, NJ, USA), at the Hormone Laboratory, Oslo Uni-
versity Hospital, Norway. Dickkopf-1 (DKK1), leptin, osteoprotegerin
(OPG), sclerostin, and tumor necrosis factor-alpha (TNF-α) were ana-
lyzed using multianalyte profiling Milliplex MAP assay, and receptor
activator of nuclear factor ĸB ligand (RANKL) by a single analyte assay
(Millipore Corporation, Billerica, MA, USA). According to the manu-
facturer the serum RANKL detection limit was 5.0 pg/mL, but the
minimum actual readout from the instrument was 0.1 pg/mL. However,
around 80% of the samples had values below detection range, and
therefore the median values for RANKL in the cohort was 0.0 pg/mL.
BMD was measured by dual-energy x-ray absorptiometry (DXA) (GE
Lunar Prodigy, Lunar Corporation, Madison, WI, USA) at the hip and
lumbar spine. For hip the total hip (mean of left and right, or one side if
not both could be measured) was used in the analyses. For the lumbar
spine L1 (which had valid measurement in almost every subject) was
used as for the other vertebrae several measurements were non-valid or
of less quality.
2.3. Statistical analyses
Normal distribution was evaluated with skewness, kurtosis and vi-
sual inspection of histograms and found normal for all parameters ex-
cept CTX-1, leptin, OPG and sclerostin that attained normal distribution
after log transformation and were used as such when being dependent
variables in regression analyses. RANKL was not normally distributed
and could not be log-transformed and therefore analyzed with non-
parametric statistics. All delta values (value at end of study minus value
at baseline) except delta RANKL were normally distributed.
Comparisons between groups at baseline were performed with the
Student's t-test or the Mann-Whitney U test. Comparisons between the
intervention and placebo groups at the end of the study were performed
with a general linear model with value at end of study as the dependent
variable, gender, and randomization status as fixed factors, and age,
BMI, and baseline value as covariates [18]. Interaction between gender
and randomization status was tested in the same model and not found
significant. Correlations were evaluated with Spearman's rho. The dis-
tributions of variables across categories of serum 25(OH)D) were
evaluated with linear regression or the Kruskal-Wallis test.
P < 0.05 (two-tailed) was considered statistically significant. Data
are presented as mean ± SD or as median (5th, 95th percentile). All
statistical analyses were performed using IBM SPSS version 25 software.
2.4. Power calculation
For the main end-point of the study, cardiovascular risk factors
(systolic blood pressure, serum LDL-cholesterol, insulin resistance
(HOMA)), a total number of 450 subjects were needed to attain a power
of 0.8 and P < 0.05 [15]. A specific power calculation of effects on the
BTMs was not performed.
2.5. Ethics
The study was approved by the Regional Committee for Medical
Research Ethics (REK NORD 2013/1464) and by the Norwegian
Medicines Agency (2013–003514-40). The study is registered at
ClinicalTrials.gov NCT02750293. All subjects gave their written in-
formed consent.




Altogether, 406 subjects not using anti-resorptive medication had
successful measurements of the BTMs. Their characteristics in relation
to gender and serum 25(OH)D are shown in Table 1. Males had sig-
nificantly lower leptin and higher TNF-α, sclerostin and BMD than fe-
males. There was a significant negative association between serum
25(OH)D and PTH (Tables 1 and 2, Fig. 1). Except for a correlation with
OPG, no significant relations between 25(OH)D and the BTMs or bone-
related substances were seen (Table 2). There were several correlations
between the BTMs and the bone-related substances, age, BMI and BMD.
There was no significant correlation between 25(OH)D and BMD
(Table 2).
3.2. Intervention study
In total, 399 subjects completed the intervention with successful
BTM measurements, 202 in the vitamin D and 197 in the placebo group.
These two groups did not differ significantly at baseline (Table 3). At
the end of the intervention, serum 25(OH)D had increased from a mean
level of 32.8 nmol/L to 88.9 nmol/L in the vitamin D group, whereas a
decline from 35.1 nmol/L to 30.6 nmol/L occurred in the placebo
group. Compared with the placebo group, there was a significant de-
crease in serum PTH, an increase in serum calcium, and a small but
significant (P < 0.01) decrease in serum P1NP. Changes in CTX-1 or
the bone-related substances did not differ significantly between the two
groups, and there were no effects on BMD (Table 3). No serious study-
drug related side effects were recorded. The compliance rate was be-
tween 84 and 100% in 14% of the subjects, and the rest had a com-
pliance rate of 100%. Two subjects developed hypercalcemia (both had
serum calcium=2.57mmol/L); one female had primary hyperpar-
athyroidism, and one male had normal serum calcium upon retesting.
Table 1
















Males/females 212/194 51/41 131/135 30/18
Current smokers/non-
smokers
86/320 47/165 39/155 21/71 58/208 7/41
Age (years) 51.9 ± 8.7 52.0 ± 9.0 51.6 ± 8.3 49.6 ± 8.0 52.5 ± 8.8 52.6 ± 8.6
BMI (kg/m2) 27.8 ± 4.9 28.1 ± 4.6 27.4 ± 5.3 27.9 ± 4.5 27.9 ± 5.1 26.8 ± 4.6
Serum calcium (mmol/L) 2.27 ± 0.07 2.26 ± 0.007 2,26 ± 0.08 2.27 ± 0.07 2.27 ± 0.08 2.28 ± 0.06
Serum PTH (pmol/L) 6.7 ± 2.0 6.6 ± 1.9 6.9 ± 2.2 7.3 ± 2.4 6.6 ± 1.9 6.2 ± 1.6⁎
Serum 25(OH)D (nmol/L) 34.0 ± 12.9 33.9 ± 13.2 34.1 ± 12.5 19.4 ± 3.9 34.4 ± 6.2 59.7 ± 9.4⁎
Serum PINP (pg/mL) 44.8 ± 15.1 44.5 ± 13.7 45.2 ± 16.6 46.6 ± 15.2 44.7 ± 15.3 42.5 ± 13.6
Serum CTX (pg/mL) 0.34 (0.18, 0.62) 0.36 (0.19, 0.67) 0.35 (0.16, 0.59) 0.37 (0.17, 0.73) 0.35 (0.17, 0.65) 0.33 (0.21, 0.59)
Serum OPG (pg/mL) 306 (192, 479) 306 (188, 498) 306 (208, 460) 292 (1981, 485) 308 (194, 479) 310 (221, 477)
Serum RANKL (pg/mL) 0.0 (0.0, 46.8) 0.0 (0.0, 55.8) 0.0 (0.0, 24.9) 0.0 (0.0, 38.7) 0.0 (0.0, 52.3) 0.0 (0.0, 33.7)
Serum TNF-α (pg/mL) 2.40 ± 0.81 2.58 ± 0.82⁎⁎⁎ 2.20 ± 0.76 2.41 ± 0.81 2.36 ± 0.79 2.61 ± 0.9
Serum sclerostin (pg/mL) 1806 (1030, 3140) 2044 (1126, 3286)⁎⁎⁎ 1642 (998, 2764) 1872 (1034, 3005) 1791 (1052, 3169) 1957 (980, 2936)
Serum DKK1 (pg/mL) 1456 ± 396 1461 ± 402 1451 ± 392 1458 ± 338 1461 ± 421 1429 ± 364
Serum Leptin (pg/mL) 11,081 (1725, 53,375) 7488 (1212, 30,290)⁎⁎⁎ 20,094 (3051, 68,867) 11,949 (1802, 51,042) 11,029 (1764, 54,815) 10,343 (752, 44,940)
BMD total hip (g/cm2)⁎⁎⁎⁎ 0.993 ± 0.133 1.032 ± 0.118⁎⁎⁎ 0.950 ± 0.136 1.008 ± 0.131 0.987 ± 0.136 0.995 ± 0.113
BMD L1 (g/cm2)⁎⁎⁎⁎ 1.067 ± 0.156 1.084 ± 0.159⁎⁎ 1.048 ± 0152 1.082 ± 0.138 1.059 ± 0.166 1.081 ± 0.138
Data are shown as mean ± SD or median (5th, 95th percentile).
⁎ P < 0.001, linear trend across groups.
⁎⁎ P < 0.05.
⁎⁎⁎ P < 0.001 vs females (Student's t-test or Mann-Whitney U test).
⁎⁎⁎⁎ 336 subjects (181 males, 155 females); 83, 218, and 35 subjects in the serum<25 nmol/L, 25–49 nmol/L, and > 49 nmol/L groups, respectively.
Table 2
Spearman's rho coefficient between age, BMI, serum calcium, PTH and 25(OH)D and bone turnover markers at baseline in 406 subjects.
Age BMI Serum calcium Serum PTH Serum 25(OH)D
Age (years) −0.083 0.071 0.132⁎⁎ 0.128⁎⁎
BMI (kg/m2) −0.083 −0.005 0.192⁎⁎ −0.028
Serum calcium (mmol/L) 0.071 −0.005 −0.120⁎ 0.061
Serum PTH (pmol/L) 0.132⁎⁎ 0.192⁎⁎ −0.120⁎ −0.171⁎⁎
Serum 25(OH)D (nmol/L) 0.128⁎⁎ −0.028 0.061 −0.171⁎⁎
Serum PINP (pg/mL) 0.045 −0.109⁎ 0.098⁎ 0.058 −0.047
Serum CTX (pg/mL) 0.128⁎⁎ −0.205⁎⁎ 0.117⁎ 0.096 −0.040
Serum OPG (pg/mL) 0.429⁎⁎ −0.041 0.052 −0.040 0.098⁎
Serum RANKL (pg/mL) −0.102⁎ 0.135⁎⁎ −0.009 −0.043 −0.100⁎
Serum TNF-α (pg/mL) 0.055 0.176⁎⁎ 0.070 0.003 0.011
Serum sclerostin (pg/mL) 0.322⁎⁎ 0.097 −0.001 −0.061 −0.013
Serum DKK1 (pg/mL) −0.112⁎ 0.200⁎⁎ 0.076 −0.005 −0.037
Serum Leptin (pg/mL) −0.064 0.642⁎⁎ −0.096 0.237⁎⁎ −0.001
BMD total hip (g/cm2)⁎⁎⁎ −0.271⁎⁎ 0.439⁎⁎ −0.012 −0.047 - 0.001
BMD L1 (g/cm2)⁎⁎⁎ −0.273⁎⁎ 0.253⁎⁎ −0.120⁎ −0.029 0.013
⁎ P < 0.050.
⁎⁎ P < 0.01 Spearman's rho.
⁎⁎⁎ n=336.
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Nine subjects in the vitamin D group had serum 25(OH)D > 125 nmol/
L at the end of the study. None of them developed hypercalcemia, and
their mean serum calcium was 2.31mmol/L.
When the two groups were pooled at the end of the study, there was
a significant increase in serum calcium and decrease in serum PTH
across categories of serum 25(OH)D (in steps of 25 nmol/L),whereas no
significant changes occurred the BTMs or bone-related substances
(Supplementary Table 1). In the same cohort, there was in particular a
negative correlation between delta serum 25(OH)D and delta PTH, a
negative correlation between delta serum 25(OH)D and delta P1NP,
and positive correlations between delta PTH and delta P1NP and delta
CTX-1. There was a positive association between delta BMI and delta
leptin (Supplementary Table 2).
3.3. Subgroup analyses
To examine potential effects in subgroups based on baseline serum
25(OH)D and serum 25(OH)D response to treatment, subjects with
baseline 25(OH)D < 40 nmol/L and final serum 25(OH)D in the vi-
tamin D group> 70 nmol/L (n= 126) and < 40 nmol/L in the pla-
cebo group (n= 121) were analyzed separately. However, similar re-
sults were found as when all subjects were included, with a mean
decrease in P1NP of 1.47 pg/ml in the vitamin D group, versus an in-
crease in the placebo group of 1.06 pg/ml (P < 0.05, linear regression
with gender, age, BMI and baseline value as covariates). Changing the
above cut-off did not reveal other positive effects, even when lowering
the baseline cut-off to< 25 nmol/L, (n= 90) (data not shown). When
analyzing separately subjects with baseline serum 25(OH)
D > 40 nmol/L, there was still a significant difference in delta P1NP
between the groups with a decrease in the vitamin D group of 0.68 pg/
ml, and an increase in the placebo group of 3.14 pg/ml (P < 0.01).
To evaluate if vitamin D effects could be related to serum PTH levels
and responses, subjects with serum PTH > 6.5 pmol/L at baseline were
selected from the intervention group if serum PTH had declined
≥1 pmol/L (n=42) and from the placebo group if no decrease in
serum PTH had occurred (n=59). In addition to a significant decrease
of P1NP in the vitamin D group, a significant decline in serum CTX-1
and an increase in serum sclerostin were seen as compared to the pla-
cebo group (Table 4).
4. Discussion
In this RCT, including 399 subjects with low 25(OH)D levels, those
given 20,000 IU vitamin D weekly for four months reached a mean
serum 25(OH)D level of 89 nmol/L, reflected in a decline in serum PTH
and increase in serum calcium. In spite of a substantial rise in 25(OH)D,
there was only a small, but significant reduction in serum P1NP.
No additional effects on BTMs or bone-related substances were seen
in 90 subjects who had baseline 25(OH)D < 25 nmol/L and with the
anticipated response to the intervention. However, in another subgroup
with baseline serum PTH > 6.5 pmol/L and with the expected PTH
response to supplementation, the reduction in P1NP was more pro-
nounced, and a significant reduction in CTX-1 occurred. Moreover, this
subgroup displayed a significant increase in serum sclerostin. This
Fig. 1. Serum PTH in relation to serum 25(OH)D in the 406 subjects at baseline.
Table 3
Baseline and end of study values in the 399 subjects who completed the four months intervention.
Vitamin D group (n= 202) Placebo group (n= 197)
Baseline End of study Baseline End of study
Males/females 108/94 104/93
Current smokers/non-smokers 44/158 44/153
Age (years) 51.5 ± 8.6 52.5 ± 8.8
BMI (kg/m2) 27.8 ± 5.0 28.0 ± 5.0 27.7 ± 4.7 27.9 ± 4.8
Serum calcium (mmol/L) 2.27 ± 0.07 2.29 ± 0.08⁎ 2.27 ± 0.07 2.27 ± 0.97
Serum PTH (pmol/L) 6.6 ± 2.2 5.9 ± 2.0⁎⁎ 6.7 ± 1.8 7.3 ± 2.1
Serum 25(OH)D (nmol/L) 32.8 ± 11.1 88.9 ± 19.4⁎⁎ 35.1 ± 13.4 30.6 ± 9.6
Serum PINP (pg/mL) 45.0 ± 15.4 43.8 ± 13.6⁎ 44.1 ± 14.8 45.6 ± 15.2
Serum CTX (pg/mL) 0.34 (0.18, 0.61) 0.35 (0.18, 0.67) 0.34 (0.17, 0.62) 0.35 (0.16, 0.60)
Serum OPG (pg/mL) 307 (200, 477) 321 (211, 497) 308 (188, 498) 318 (194, 524)
Serum RANKL (pg/mL) 0 (0, 42.1) 0 (0, 72.9) 0 (0, 46.8) 0 (0, 80.0)
Serum TNF-α (pg/mL) 2.37 ± 0.79 2.63 ± 0.77 2.39 ± 0.82 2.67 ± 0.86
Serum sclerostin (pg/mL) 1815 (1063, 3054) 2159 (1321, 3553) 1818 (998, 3181) 2147 (1217, 3509)
Serum DKK1 (pg/mL) 1476 ± 380 1605 ± 420 1442 ± 411 1573 ± 454
Serum Leptin (pg/mL) 11,243 (1693, 53,375) 12,561 (1575, 59,002) 10,877 (1764, 50,797) 11,983 (2239, 52,890)
BMD total hip (g/cm2)⁎⁎⁎ 1.001 ± 0.135 1.001 ± 0.136 0.985 ± 0.136 0.987 ± 0.137
BMD L1 (g/cm2)⁎⁎⁎ 1.074 ± 0.159 1.077 ± 0.161 1.056 ± 0.153 1.056 ± 0.155
Data are shown as mean ± SD or median (5th, 95th percentile).
⁎ P < 0.01.
⁎⁎ P < 0.001, versus placebo group, linear regression with age, gender, BMI and baseline value as covariates.
⁎⁎⁎ N=336, 166 in the vitamin D group and 170 in the placebo group.
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indicates that in subjects with “functional” vitamin D deficiency, vi-
tamin D supplementation leads to reduced bone turnover through
suppression of PTH.
This inhibition of bone turnover is consistent with observational
data where vitamin D deficiency appears to be associated with in-
creased bone turnover [7]. We measured CTX-1 and P1NP for assess-
ment of bone turnover as recommended by the International Osteo-
porosis Foundation, and these markers have been included in the
majority of studies on vitamin D and BTMs [19]. Most studies have
found no effect of vitamin D supplementation [12–14], but slight re-
ductions in CTX-1 [20] and P1NP [21] have also been reported. How-
ever, none of these studies included an adequate number of subjects
with vitamin D deficiency and gave sufficient vitamin D doses, as was
done in our study.
As anticipated, the effect on P1NP and CTX-1 in the current study
was small compared with conventional antiresorptive drugs. We ob-
served a decline in serum P1NP of 6.0% after four months of vitamin D
supplementation (compared to the placebo group), as opposed to a
reduction in CTX-1 and P1NP of 40% after treatment with oral bi-
sphosphonates [22]. Nevertheless, vitamin D administration was shown
to induce an additional reduction in CTX-1 of 25% in postmenopausal,
osteoporotic women with serum 25(OH)D < 50 nmol/L treated with
alendronate [23]. In line with this, in subjects on antiresorptive treat-
ment a significantly higher BMD and lower fracture rate have been
observed in those with 25(OH)D above 50 nmol/L compared to those
below [24]. Thus, the response to antiresorptive treatment of post-
menopausal osteoporosis seems to depend on vitamin D status.
Meta-analyses on pooled data from randomized trials on vitamin D
supplementation and skeletal effects, show only a small, positive effect
at the femoral neck and a modest fracture reduction [25]. The role of
vitamin D in preserving bone health has therefore been questioned.
However, the majority of the populations included had normal baseline
levels of 25(OH)D, and thus the results may not apply to individuals
with low 25(OH)D levels. In contrast, Chapuy reported a 2.7% increase
at proximal femur BMD and 32 and 43% lower risk, respectively, of
non-vertebral and hip fractures in elderly with serum 25(OH)D le-
vels< 50 nmol/L given calcium and vitamin D supplements [10]. In
spite of these substantial skeletal effects, no change occurred in the
bone formation marker osteocalcin. Similarly, Dawson-Hughes
observed a 2.6% rise in spine BMD and a decline by 50% in vertebral
fractures after 3 years with vitamin D and calcium supplements [26].
They observed a decline in PTH and osteocalcin, whereas bone re-
sorption assessed by 24-h urinary N-telopeptide/creatinine ratio did not
differ between groups. These studies suggest that BTMs not necessarily
reflect the skeletal effects of vitamin D supplementation, and may not
be the appropriate tool to assess thresholds for vitamin D sufficiency.
An alternative interpretation could be that the definition of vitamin D
deficiency might need to be re-appraised.
The size of the dosage and whether supplements are given daily or
intermittently as in the current study, could also affect the BTMs re-
sponse. Previous studies have suggested that large intermittent doses
may have adverse effects with a transient increase in fracture and fall
risk in spite of adequate vitamin D levels [27,28]. Rossini et al. ob-
served an acute rise in CTX-1 and cross-linked N-telopeptide of type I
collagen after a single oral dose of 600,000 IU vitamin D, whereas bone-
specific alkaline phosphatase was unaffected [29]. A loading dose of
300,000 IU vitamin D has also been shown to induce supraphysiological
levels of 1,25(OH)2D and a rise in the osteocyte-products sclerostin and
fibroblast growth factor 23 (FGF23) [30,31], resulting both in inhibi-
tion of bone formation and mineralization [32–34], and stimulation of
bone resorption. Thus, these substances are proposed to mediate the
adverse skeletal effects observed after a high dose with vitamin D. A rise
in 1,25(OH)2D and FGF23 has also been observed at a daily dosage of
2800 IU vitamin D [35], which corresponds to the weekly dose of
20,000 IU in our study.
Dawson Hughes et al. also reported a rise in sclerostin after three
years with 800 IU vitamin D in combination with calcium [26]. Pre-
sumably, the mechanism for the rise in sclerostin is different when vi-
tamin D is given in a high loading dose compared to a daily dose of
800 IU. In the latter case, the elevation could be attributed to a higher
bone mass and a larger pool of osteocytes, as indicated by some studies
[36]. Thus, in a recent study, vitamin D deficiency was associated with
decreased number of viable osteocytes in human iliac crest and vitamin
D was shown to promote the transition of osteoblasts to osteocytes and
to play a role in regulation of osteocyte number [37]. Whether the
higher sclerostin level observed in the subgroup analysis in our study is
due to a vitamin D-induced increase of osteocytes and a higher bone
mass remains to be seen.
Table 4
Baseline and end of study values in subjects who at baseline had serum PTH > 6.5 pmol/L and for those in the vitamin D group with a decrease in serum
PTH > 1 pmol/l and for those in the placebo group that did not have a decrease in serum PTH by the end of the study.
Vitamin D group (n= 42) Placebo group (n= 59)
Baseline End of study Baseline End of study
Males/females 25/17 29/30
Current smokers/non-smokers 5/37 9/50
Age (years) 52.0 ± 7.9 55.1 ± 8.6
BMI (kg/m2) 28.8 ± 5.3 28.8 ± 5.3 28.2 ± 4.5 28.3 ± 4.5
Serum calcium (mmol/L) 2.27 ± 0.07 2.30 ± 0.07 2.28 ± 0.08 2.26 ± 0.08
Serum PTH (pmol/L) 9.1 ± 2.6⁎ 6.6 ± 2.1⁎⁎⁎ 8.0 ± 1.3 9.3 ± 1.7
Serum 25(OH)D (nmol/L) 30.4 ± 10.3⁎ 87.4 ± 20.8⁎⁎⁎ 35.1 ± 12.7 28.5 ± 8.3
Serum PINP (pg/mL) 48.6 ± 19.7 44.0 ± 13.4⁎⁎⁎ 46.8 ± 15.6 49.1 ± 16.9
Serum CTX (pg/mL) 0.38 (0.21, 0.66) 0.35 (0.18, 0.69)⁎⁎ 0.37 (0.19, 0.74) 0.41 (0.19, 0.69)
Serum OPG (pg/mL) 287 (205, 431) 291 (190, 490) 305 (215, 512) 305 (206, 540)
Serum RANKL (pg/mL) 0.0 (0.0, 38.5) 0.0 (0.0, 83.9) 0.0 (0.0, 28.2) 4.7 (0.0, 80.0)
Serum TNF-α (pg/mL) 2.17 ± 0.77 2.57 ± 0.87 2.40 ± 0.89 2.79 ± 0.93
Serum sclerostin (pg/mL) 1734 (1059, 2995) 2200 (1398, 3482)⁎⁎ 1876 (998, 3180) 2087 (1398, 3515)
Serum DKK1 (pg/mL) 1405 ± 343 1620 ± 417 1419 ± 381 1556 ± 494
Serum Leptin (pg/mL) 12,875 (3303, 53,330) 12,915 (4231, 60,209) 14,871 (1851, 58,217) 14,820 (2697, 56,397)
BMD total hip (g/cm2)⁎⁎⁎⁎ 1.031 ± 0.157 1.031 ± 0.156 0.950 ± 0.134 0.952 ± 0.132
BMD L1 (g/cm2)⁎⁎⁎⁎ 1.078 ± 0.161 1.080 ± 0.162 1.025 ± 0.151 1.019 ± 0.149
Data are shown as mean ± SD or median (5th, 95th percentile).
⁎ P < 0.05; versus placebo group, Student's t-test.
⁎⁎ P < 0.05 versus placebo group, linear regression with delta value as dependent variable and age, gender, BMI and baseline value as covariates.
⁎⁎⁎ P < 0.001, versus placebo group, linear regression with end of study as dependent variable and age, gender, BMI and baseline value as covariates.
⁎⁎⁎⁎ n=37 in the vitamin D group, 54 in the placebo group.
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P1NP and CTX-1 are indicators of bone turnover, but do not provide
information on which pathways an intervention works. To elucidate
this, we measured several substances involved in regulation of bone
metabolism. Apart from sclerostin, no differences were seen in RANKL,
OPG, TNF-α or leptin levels, which at least for TNF- α and leptin are in
accordance with previous publications [38,39].
Effects of vitamin D on bone depend on the calcium status. If in
calcium deficit, VDR stimulation leads to bone resorption to maintain
the serum calcium level, whereas positive effects on bone metabolism
prevail when the calcium supply is adequate [1]. Consequently, vitamin
D supplementation is not effective or may even exaggerate bone loss if
not combined with sufficient calcium intake. Unfortunately, data on
calcium intake were not available in the present study. However, a
previous study reported a daily calcium intake of about 500mg in our
population [40], which is insufficient according to the recommenda-
tions of The Institute of Medicine [3]. Since low serum calcium is a
potent stimulus of PTH secretion, this may partly counteract the sup-
pressive effect of vitamin D supplementation on PTH and BTMs.
Hypomagnesemia could also attenuate the effect of vitamin D sup-
plements on BTMs by blunting the PTH response [41,42]. One could
therefore speculate that subjects with increased serum PTH level who
responded with a decline in PTH and BTMs after vitamin D supple-
mentation, had vitamin D deficiency without concomitant calcium or
magnesium insufficiency. In contrast, the more modest effect on BTMs
in the subgroup with low vitamin D status alone could be attributed to
insufficient calcium or magnesium intake.
Our study has several limitations. As mentioned above, we did not
have information on calcium intake, which may be low in our popu-
lation [40]. Our results may therefore not apply to populations with a
higher intake of calcium. Even though all subjects at screening were
insufficient according to the standard criterion (serum 25(OH)
D < 50 nmol/L) [3], none displayed extreme vitamin D deficiency
(serum 25(OH)D < 10 nmol/L), and most were not functionally vi-
tamin D deficient. The subgroup analysis based on serum PTH levels
and responses was not pre-specified, and even though the results were
biologically plausible, should be viewed with caution. Furthermore, the
effect on BTMs probably reaches its maximum when optimal level of
vitamin D level is acquired, thereafter tapering off. Given the potential
negative effects of high-dose vitamin D [30–34], the BTMs should
therefore ideally have been measured directly after intake of the sup-
plements and at several time points thereafter to capture the fluctua-
tions in bone metabolism. There was no correlation between serum
25(OH)D and BMD, probably due to including mainly subjects with low
serum 25(OH)D levels. And finally, the observation period was too
short for evaluating effects on BMD.
On the other hand, our study has considerable strengths as we in-
cluded the largest group of subjects with vitamin D deficiency so far
studied regarding BTMs, and achieved serum 25(OH)D levels above
70 nmol/L in nearly all subjects. We found the expected relations be-
tween the BTMs and age, BMI, and gender, and the vitamin D supple-
mentation caused significant increase in serum calcium and reduction
in PTH, which give the study considerable internal strength.
4.1. Concluding remarks
The main lesson from our study is that vitamin D supplementation
has minor effects on BTMs in subjects without extreme vitamin D de-
ficiency. Thus, BTMs are probably not useful in monitoring skeletal
response to vitamin D supplements. Intervention studies including
subjects with higher baseline serum 25(OH)D than in our study, should
be discouraged.
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